Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day
一项多中心、随机、双盲 II 期研究对接受乐伐替尼 18 或 24 mg/天治疗的分化型甲状腺癌患者进行了健康相关生活质量分析。
期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.5308
Taylor, Matthew H; Leboulleux, Sophie; Panaseykin, Yury; Konda, Bhavana; de La Fouchardiere, Christelle; Hughes, Brett G M; Gianoukakis, Andrew G; Park, Young Joo; Romanov, Ilia; Krzyzanowska, Monika K; Garbinsky, Diana; Sherif, Bintu; Pan, Jie Janice; Binder, Terri A; Sauter, Nicholas; Xie, Ran; Brose, Marcia S